Addition of a boost improved anti-viral immunity associated with correlates of HIV-1 risk.

<p>Heatmap of 28 immune response variables longitudinally analyzed at RV144 peak immunogenicity (week 26) and two weeks post first and second RV305 boosts (weeks 2 and 26, respectively). All data was log10-transformed and then each variable [measurement type (BAMA MFI, BAMA breadth score, and...

Full description

Saved in:

Bibliographic Details
Main Author:	LaTonya D. Williams (3140490) (author)
Other Authors:	Xiaoying Shen (164029) (author), Sheetal S. Sawant (15999375) (author), Siriwat Akapirat (673316) (author), Lindsay C. Dahora (7633568) (author), Matthew Zirui Tay (3140493) (author), Sherry Stanfield-Oakley (2361535) (author), Saintedym Wills (15999378) (author), Derrick Goodman (4591453) (author), DeAnna Tenney (15999381) (author), Rachel L. Spreng (7633574) (author), Lu Zhang (50563) (author), Nicole L. Yates (7163783) (author), David C. Montefiori (7392644) (author), Michael A. Eller (8928134) (author), David Easterhoff (3780034) (author), Thomas J. Hope (8087966) (author), Supachai Rerks-Ngarm (190865) (author), Punnee Pittisuttithum (15999384) (author), Sorachai Nitayaphan (289303) (author), Jean-Louis Excler (132268) (author), Jerome H. Kim (8415000) (author), Nelson L. Michael (7392548) (author), Merlin L. Robb (7392551) (author), Robert J. O’Connell (15999387) (author), Nicos Karasavvas (289298) (author), Sandhya Vasan (102251) (author), Guido Ferrari (164054) (author), Georgia D. Tomaras (7163792) (author)
Published:	2023
Subjects:	Medicine Microbiology Neuroscience Physiology Immunology Cancer Mental Health Infectious Diseases Virology Computational Biology viral vector immunogen putative immune correlates previous reports demonstrated plasma env iga fc effector functions e gp120 ). canarypox viral vector 6 &# 8211 humoral responses elicited driving antibody specificity specifically iga1 ), shot immunization series e gp120 alone dependent cellular cytotoxicity 3 years following 1 epitope specificity elicited antibody responses uninfected rv144 recipients primary rv144 regimen achieve protective immunity 1 immunity post 1 antibody specificity v1v2 env igg3 modestly efficacious hiv different booster immunogens decreased infection risk antibody fc function 1 vaccine regimen specifically antibody protective immunity cellular responses booster immunization 1 risk rv144 immunogens antibody subclass hiv alone decreased hiv 8 years 1 strains xlink "> vaccine efficacy specific antibodies results reveal rapid waning new strategies lower hiv increase magnitude higher levels heterologous hiv extended boosts critically needed conferred 31 complex dynamic aidsvax b
Tags:	Add Tag No Tags, Be the first to tag this record!

Addition of a boost improved anti-viral immunity associated with correlates of HIV-1 risk.

Similar Items